Introducing Our Most Robust Muscular Dystrophy/Myopathy Panels

Muscular dystrophies and myopathies are complex conditions and we strive to stay at the forefront of genetics to provide you with the best answers possible. The correct genetic diagnosis is vital to the patient meaning pinpointing treatment options and therapies, and opening up the possibility of clinical trial enrollment downstream. MNG Laboratories has made substantial improvements […]

MNG Laboratories is Now Offering Enhanced Ataxia Panels

Our Ataxia Panel Portfolio MNG Laboratories has expanded our Ataxia/Episodic Ataxia testing to include sequencing of 330 genes with copy number analysis, mtDNA sequencing & deletion, and most notably, the Spinocerebellar Ataxia (SCA) repeat expansions. Not only is our core panel improved and broadened; we’ve also included the repeat expansions necessary to enhance the diagnostic power of […]

Improved Epilepsy Portfolio

Our Epilepsy Portfolio When it comes to a Comprehensive Epilepsy Panel, it’s not just about the number of genes in that panel. You should expect a lab to know how to find a pathogenic variant that could be the cause of your patients’ conditions, regardless of the number of genes that should be analyzed. In addition to […]

MNG Laboratories is Now CAP and CLIA Accredited

On September 26, 2016, MNG Laboratories announced its accreditation from the College of American Pathologists (CAP). CAP aims to improve patient safety by advancing the quality of pathology and laboratory services through education, standard setting, and ensuring laboratories meet or exceed regulatory requirement. As of now, CAP accredits more than 7,600 laboratories globally. Read more about this exciting […]